The ANCHOR Study

• Research type

  Research Study

• Full title

  A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications – The ANCHOR Study

• IRAS ID

  1012419

• Contact name

  William Alexander

• Contact email

  jalexander@cidara.com

• Sponsor organisation

  Cidara Therapeutics, Inc.

• Research summary

  The ANCHOR study aims to test a new drug called CD388 that could help prevent seasonal flu, which affects millions worldwide each year. While flu vaccines exist, they don't always work well, especially for people with weakened immune systems or other health issues. This study seeks to find a better way to protect people throughout the flu season.

  About 5,500 people will participate in this study across five countries: Argentina, Australia, South Africa, the United Kingdom, and the United States. The main goals are to check if CD388 is safe for a large group of people and if it works better than a placebo in preventing flu symptoms.

  Participants will be randomly assigned to one of two groups:
  1. CD388 group
  2. Placebo group

  Each person has an equal chance of being in either group. The study is "double-blind," meaning neither the participants nor the researchers will know who receives CD388 or the placebo during the study. This helps ensure fair results.

  Throughout the study, participants will attend clinic visits and receive their assigned treatment. The study doctor can find out which treatment a participant received if it's necessary for their safety.

  CD388 is not a vaccine but a potential new medicine that could offer protection against the flu, even for those whose immune systems don't respond well to vaccines. This research is important because it may lead to better flu prevention methods, especially for high-risk individuals, and help address the ongoing challenge of changing flu viruses and the potential for new, more dangerous strains.

• REC name

  West of Scotland REC 1

• REC reference

  25/WS/0136

• Date of REC Opinion

  30 Sep 2025

• REC opinion

  Further Information Favourable Opinion